Hearing Loss Trial, Recruiting NCT05917496 Sponsor: Assistance Publique - Hôpitaux de Paris Condition: Hearing Loss
Back to Hearing Loss

Hearing Loss Trial, Recruiting

NCT05917496
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Children who were born with profound deafness
  • Children who received their cochlear implant between 8 months and 18 months of age
  • Children who have had a cochlear implant (in one or both ears) for at least 3 months
  • Children who are between 11 months and 21 months old on the day they enter the study
  • Children who wear their cochlear implant consistently every day
  • Children who are receiving speech therapy
  • Children who have at least one parent who speaks French
  • Children whose parents or legal guardians have been informed about the study and have agreed to participate

Who may not be able to join:

  • Children whose deafness is part of a broader genetic syndrome, or who have an absent or underdeveloped hearing nerve
  • Children with a very small inner ear structure, or where the implant electrode was not fully inserted
  • Children diagnosed with CHARGE syndrome (a condition affecting multiple parts of the body including the eyes, heart, airways, growth, and ears)
  • Children whose deafness is linked to significant brain involvement caused by conditions such as cytomegalovirus (a viral infection) or meningitis
  • Children with a confirmed condition that is known to affect language development, such as Autism Spectrum Disorder or significant intellectual disability
  • Children who do not wear their cochlear implant every day
  • Children with confirmed vision problems that have not been corrected and that would interfere with the language assessment tests used in the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Clara LEGENDRE, speech therapist, Assistance Publique - Hôpitaux de Paris

Phone: 1 71 39 67 96

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
13 September 2024
Est. completion
1 July 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Number of conversation turns; Receptive lexical level; Correlation between the number of conversation turns parameter and the receptive lexical level

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov